SARomics Biostructures AB

SARomics Biostructures and Red Glead Discovery enter lead discovery collaboration in the field of epigenetic disorders

Pressmeddelande   •   Okt 25, 2012 08:12 CEST

Lund, Sweden, October 25, 2012 – SARomics Biostructures and Red Glead Discovery announce today that they have entered into a drug discovery collaboration. Within the alliance, the two companies will perform a joint collaborative project with the goal of developing novel lead compounds against epigenetic pathway targets. Targeting proteins involved in epigenetic mechanisms (the cellular processes associated with the modification of chromatin) have emerged as an important new therapeutic opportunity for treating cancer, diabetes, inflammatory diseases and more.

By merging the unique and highly complementary capabilities of the two companies, an efficient and versatile fragment-based lead discovery (FBLD) platform is enabled. The advanced structural biology platform and expertise contributed by SARomics Biostructures are combined with the bioassay technology and medicinal chemistry skills of Red Glead Discovery. The scientific excellence of the alliance is reflected by the track record of Red Glead Discovery for delivery of lead compounds and the established platform for structure-based drug design implemented by SARomics Biostructures.

For the project, the companies will share costs and the generated intellectual property rights. Project progress and the discovery of lead compounds will be effectuated by utilisation of FBLD, which is a powerful alternative to costly and resource-intensive high-throughput screening (HTS) campaigns. At this stage of the project, the collaboration will be run without external financing.

Björn Walse, CEO of SARomics Biostructures, said “We are excited about the opportunity to work with Red Glead Discovery on this frontline project that clearly leverages the competitiveness of both companies. We see this initiative as highly complementary to SARomics’ other collaborations, such as those within KINOMED, which focus on protein kinase off-the-shelf crystal structures and fragment complexes.”

Johan Evenäs, CEO of Red Glead Discovery, added ” I am convinced that we have a perfect match of competences and experiences enabling a project that would have been difficult for either company alone at this stage. We expect the close proximity of our two companies within the Lund Life Science Incubator at Medicon Village to further facilitate effective collaboration.”

Additional details about both companies:

About Red Glead Discovery

Red Glead Discovery is a small molecule lead discovery company founded in 2011 as a spin-out from AstraZeneca and is privately owned. Red Glead Discovery offers first-rate contract drug discovery services and generates new commercial drug discovery projects (co-developed with academic and/or financing partners). The company provides access to cross-disciplinary expertise of high scientific standard within medicinal and analytical chemistry, assay development and screening, radioisotope labeling, as well as physicochemical and metabolic profiling. Red Glead Discovery possesses the skill set required to drive preclinical projects from a target idea to the generation of lead compounds with high potential to be developed into novel therapies. For more information, please visit the company’s website or contact Dr. Johan Evenäs at


About SARomics Biostructures

SARomics Biostructures is the leading Scandinavian provider of structural biology and in silico drug discovery services. The company accelerates its customers’ drug discovery processes by providing structure-based drug design support including protein crystallization, X-ray protein structure determination, computational chemistry, protein modeling and NMR spectroscopy analyses. The company is equipped with state-of-the-art robotics for low volume high-throughput crystallization and X-ray diffraction experiments. Its strategic location close to the MAX-lab synchrotron radiation facility provides the company with instant access to beamlines. For further general information please visit or contact Dr. Björn Walse, CEO at